135 related articles for article (PubMed ID: 30741938)
1. Most canine ameloblastomas harbor HRAS mutations, providing a novel large-animal model of RAS-driven cancer.
Saffari PS; Vapniarsky N; Pollack AS; Gong X; Vennam S; Pollack AJ; Verstraete FJM; West RB; Arzi B; Pollack JR
Oncogenesis; 2019 Feb; 8(2):11. PubMed ID: 30741938
[TBL] [Abstract][Full Text] [Related]
2. Ultra-frequent HRAS p.Q61R somatic mutation in canine acanthomatous ameloblastoma reveals pathogenic similarities with human ameloblastoma.
Peralta S; McCleary-Wheeler AL; Duhamel GE; Heikinheimo K; Grenier JK
Vet Comp Oncol; 2019 Sep; 17(3):439-445. PubMed ID: 31041834
[TBL] [Abstract][Full Text] [Related]
3. Confirmation of canine acanthomatous ameloblastoma using RAS Q61R immunohistochemical staining of formalin-fixed paraffin-embedded tissues.
Peralta S; Marcinczyk MM; Katt WP; Duhamel GE
Front Vet Sci; 2023; 10():1281022. PubMed ID: 37901104
[TBL] [Abstract][Full Text] [Related]
4. Comparative transcriptional profiling of canine acanthomatous ameloblastoma and homology with human ameloblastoma.
Peralta S; Duhamel GE; Katt WP; Heikinheimo K; Miller AD; Ahmed F; McCleary-Wheeler AL; Grenier JK
Sci Rep; 2021 Sep; 11(1):17792. PubMed ID: 34493785
[TBL] [Abstract][Full Text] [Related]
5. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas.
Kumamoto H; Takahashi N; Ooya K
J Oral Pathol Med; 2004 Jul; 33(6):360-7. PubMed ID: 15200485
[TBL] [Abstract][Full Text] [Related]
6. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
[TBL] [Abstract][Full Text] [Related]
7. Ki67 Labelling Index of Neoplastic Epithelial Cells Differentiates Canine Acanthomatous Ameloblastoma from Oral Squamous Cell Carcinoma.
Peralta S; Grenier JK; McCleary-Wheeler AL; Duhamel GE
J Comp Pathol; 2019 Aug; 171():59-69. PubMed ID: 31540626
[TBL] [Abstract][Full Text] [Related]
8. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
9. Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.
Untch BR; Dos Anjos V; Garcia-Rendueles MER; Knauf JA; Krishnamoorthy GP; Saqcena M; Bhanot UK; Socci ND; Ho AL; Ghossein R; Fagin JA
Cancer Res; 2018 Aug; 78(16):4642-4657. PubMed ID: 29760048
[TBL] [Abstract][Full Text] [Related]
10. Nuclear morphometry in canine acanthomatous ameloblastomas and squamous cell carcinomas.
Martano M; Damiano S; Restucci B; Paciello O; Russo V; Maiolino P
Eur J Histochem; 2006; 50(2):125-30. PubMed ID: 16864123
[TBL] [Abstract][Full Text] [Related]
11. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours.
Diniz MG; Gomes CC; Guimarães BV; Castro WH; Lacerda JC; Cardoso SV; de Faria PR; Dias FL; Eisenberg AL; Loyola AM; Gomez RS
Tumour Biol; 2015 Jul; 36(7):5649-53. PubMed ID: 25854168
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characterization of Canine Acanthomatous Ameloblastoma (CAA) in 263 dogs and the Influence of Postsurgical Histopathological Margin on Local Recurrence.
Goldschmidt SL; Bell CM; Hetzel S; Soukup J
J Vet Dent; 2017 Dec; 34(4):241-247. PubMed ID: 28978273
[TBL] [Abstract][Full Text] [Related]
13. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Cronise KE; Hernandez BG; Gustafson DL; Duval DL
Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
[TBL] [Abstract][Full Text] [Related]
14. The landscape of genetic alterations in ameloblastomas relates to clinical features.
Gültekin SE; Aziz R; Heydt C; Sengüven B; Zöller J; Safi AF; Kreppel M; Buettner R
Virchows Arch; 2018 May; 472(5):807-814. PubMed ID: 29388014
[TBL] [Abstract][Full Text] [Related]
15. The expression of calretinin and cytokeratins in canine acanthomatous ameloblastoma and oral squamous cell carcinoma.
Fulton A; Arzi B; Murphy B; Naydan DK; Verstraete FJ
Vet Comp Oncol; 2014 Dec; 12(4):258-65. PubMed ID: 22985095
[TBL] [Abstract][Full Text] [Related]
16. Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.
Decker B; Parker HG; Dhawan D; Kwon EM; Karlins E; Davis BW; Ramos-Vara JA; Bonney PL; McNiel EA; Knapp DW; Ostrander EA
Mol Cancer Res; 2015 Jun; 13(6):993-1002. PubMed ID: 25767210
[TBL] [Abstract][Full Text] [Related]
17. Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.
Mochizuki H; Breen M
Vet Comp Oncol; 2017 Dec; 15(4):1598-1605. PubMed ID: 27714944
[TBL] [Abstract][Full Text] [Related]
18. Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review.
González-González R; López-Verdín S; Lavalle-Carrasco J; Molina-Frechero N; Isiordia-Espinoza M; Carreón-Burciaga RG; Bologna-Molina R
World J Clin Oncol; 2020 Jan; 11(1):31-42. PubMed ID: 31976308
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of MDM2 protein in ameloblastomas as compared to adenomatoid odontogenic tumor.
Krishna A; Kaveri H; Naveen Kumar RK; Kumaraswamy KL; Shylaja S; Murthy S
J Cancer Res Ther; 2012; 8(2):232-7. PubMed ID: 22842367
[TBL] [Abstract][Full Text] [Related]
20. The Mutational Profile of Unicystic Ameloblastoma.
Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
